These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38980503)

  • 1. Correction: Clinical features of patients with hepatocellular carcinoma treated with radiofrequency ablation therapy: developing a simple score to determine the need for immune-adjuvant therapy.
    Tada F; Hiraoka A; Nakatani K; Matsuoka K; Fukumoto M; Matsuda T; Yanagihara E; Saneto H; Murakami T; Onishi K; Izumoto H; Kitahata S; Kanemitsu-Okada K; Kawamura T; Kuroda T; Hanaoka J; Watanabe J; Ohtani H; Yoshida O; Hirooka M; Miyata H; Tsubouchi E; Abe M; Matsuura B; Ninomiya T; Hiasa Y
    Clin J Gastroenterol; 2024 Oct; 17(5):999-1000. PubMed ID: 38980503
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical features of patients with hepatocellular carcinoma treated with radiofrequency ablation therapy: developing a simple score to determine the need for immune-adjuvant therapy.
    Tada F; Hiraoka A; Nakatani K; Matsuoka K; Fukumoto M; Matsuda T; Yanagihara E; Saneto H; Murakami T; Onishi K; Izumoto H; Kitahata S; Kanemitsu-Okada K; Kawamura T; Kuroda T; Hanaoka J; Watanabe J; Ohtani H; Yoshida O; Hirooka M; Miyata H; Tsubouchi E; Abe M; Matsuura B; Ninomiya T; Hiasa Y
    Clin J Gastroenterol; 2024 Jun; 17(3):401-411. PubMed ID: 38528198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment.
    Liang X; Bu J; Jiang Y; Zhu S; Ye Q; Deng Y; Lu W; Liu Q
    Int J Hyperthermia; 2024; 41(1):2355279. PubMed ID: 38767372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
    Majumdar A; Roccarina D; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011650. PubMed ID: 28351116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma (3-5 cm): a Propensity Score Matching Cohort Study.
    Ye QW; Pang SJ; Yang N; Zhang HB; Fu Y; Lin B; Yang GS
    J Gastrointest Surg; 2019 Aug; 23(8):1549-1558. PubMed ID: 31197690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of adjuvant transcatheter arterial chemoembolization following repeated curative resection/ablation for hepatocellular carcinoma with early recurrence: a propensity score matching analysis.
    Huang K; Qian T; Chen W; Lao M; Li H; Lin WC; Chen BW; Bai X; Gao S; Ma T; Liang T
    BMC Cancer; 2024 May; 24(1):620. PubMed ID: 38773564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
    Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
    J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes.
    Lee S; Kang TW; Cha DI; Song KD; Lee MW; Rhim H; Lim HK; Sinn DH; Kim JM; Kim K
    J Hepatol; 2018 Jul; 69(1):70-78. PubMed ID: 29524532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microwave ablation versus radiofrequency ablation for subcapsular hepatocellular carcinoma: a propensity score-matched study.
    Zheng H; Liu K; Yang Y; Liu B; Zhao X; Chen Y; Feng Y; Meng M; Tan X; Zhu Q
    Eur Radiol; 2022 Jul; 32(7):4657-4666. PubMed ID: 35092477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study of the risk factors for recurrence of early and late stage hepatocellular carcinoma after hepatic artery embolization combined with radiofrequency ablation therapy].
    Sun Y; Zhang HH; Zheng JS; Zhang YH
    Zhonghua Gan Zang Bing Za Zhi; 2021 Oct; 29(10):1001-1005. PubMed ID: 34814396
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic Impact of Indocyanine Green Plasma Disappearance Rate in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: A Prognostic Nomogram Study.
    Azumi M; Suda T; Terai S; Akazawa K
    Intern Med; 2017; 56(9):1001-1007. PubMed ID: 28458303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy.
    Goldberg SN; Kamel IR; Kruskal JB; Reynolds K; Monsky WL; Stuart KE; Ahmed M; Raptopoulos V
    AJR Am J Roentgenol; 2002 Jul; 179(1):93-101. PubMed ID: 12076912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of postoperative recurrence of hepatocellular carcinoma with radiofrequency ablation comparing with repeated surgical resection].
    Ren ZG; Gan YH; Fan J; Chen Y; Wu ZQ; Qin LX; Ge NL; Zhou J; Xia JL; Wang YH; Ye QH; Wang L; Ye SL
    Zhonghua Wai Ke Za Zhi; 2008 Nov; 46(21):1614-6. PubMed ID: 19094752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Simple Method to Avoid Bile Duct Injury during Percutaneous Radiofrequency Ablation Therapy for Hepatocellular Carcinoma.
    Takashima H; Moriguchi M; Hayashi N; Ikeda K; Ogiso K; Yokomizo C; Uejima H; Itoh T; Tomioka H; Mizuno S; Shimizu S; Yasui K; Itoh Y
    Case Rep Oncol; 2020; 13(3):1337-1342. PubMed ID: 33362515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma.
    Rossi S; Di Stasi M; Buscarini E; Cavanna L; Quaretti P; Squassante E; Garbagnati F; Buscarini L
    Cancer J Sci Am; 1995; 1(1):73-81. PubMed ID: 9166457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.
    Wade R; South E; Anwer S; Sharif-Hurst S; Harden M; Fulbright H; Hodgson R; Dias S; Simmonds M; Rowe I; Thornton P; Eastwood A
    Health Technol Assess; 2023 Dec; 27(29):1-172. PubMed ID: 38149643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma.
    Galandi D; Antes G
    Cochrane Database Syst Rev; 2004; (2):CD003046. PubMed ID: 15106188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial.
    Vietti Violi N; Duran R; Guiu B; Cercueil JP; Aubé C; Digklia A; Pache I; Deltenre P; Knebel JF; Denys A
    Lancet Gastroenterol Hepatol; 2018 May; 3(5):317-325. PubMed ID: 29503247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiofrequency Ablation Duration per Tumor Volume May Correlate with Overall Survival in Solitary Hepatocellular Carcinoma Patients Treated with Radiofrequency Ablation Plus Lyso-Thermosensitive Liposomal Doxorubicin.
    Celik H; Wakim P; Pritchard WF; Castro M; Leonard S; Karanian JW; Dewhirst MW; Lencioni R; Wood BJ
    J Vasc Interv Radiol; 2019 Dec; 30(12):1908-1914. PubMed ID: 31409568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Factors of Treatment Outcomes After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in the Hepatocaval Confluence: A Propensity Score Matching Analysis.
    Zhou Y; Yuan K; Yang Y; Shan X; Ji Z; Zhou D; Ouyang J; Wang Z; Zhang Q; Zhou J; Li Q
    Acad Radiol; 2023 Sep; 30 Suppl 1():S92-S103. PubMed ID: 37173236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.